Pharma BD Deal Intelligence
AstraZeneca to acquire Ardea for $32 per share, $1.26 billion, a 54% premium to the prior close; lead product lesinurad is in Phase III for chronic management…
AZ CEO David Brennan called the lesinurad Phase III programme 'an excellent opportunity to leverage AstraZeneca's global specialty and primary care sales…
AstraZeneca PLC completes acquisition of Ardea Biosciences, finalizing the $1.26 billion deal that adds the Phase III gout candidate lesinurad to AstraZeneca's…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
AstraZeneca acquired Ardea Biosciences at $32/share cash, total ~$1.26B (50% premium to 1-month VWAP). Added Phase 3 lesinurad for gout plus next-gen URAT1 inhibitor RDEA3170 (Phase 1).
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Ardea Biosciences, Inc. (this deal) | 2012 | $1.3B | 22 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2012 deals · AstraZeneca PLC deals · Nephrology deals